このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

難治性脊髄転移の治療のためのNOVOTTF-200MおよびNOVO TTF-200AシステムのフェーズI研究

2026年10月5日 更新者:M.D. Anderson Cancer Center

This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.

調査の概要

詳細な説明

Primary Objective:

To evaluate the safety of applying TTFields at frequencies between 150 and 200KHz, using the TTF200M and TTF-200A systems (respectively), alone or in combination with available systemic therapies as adjuvant treatment in patients with radiation refractory spinal metastasis. Safety will be specifically assessed based on absence of wound dehiscence in the surgical group and severe cellulitis requiring drainage and intravenous antibiotics in both surgical and non-surgical cohorts.

Secondary Objective:

To assess local spine progression-free survivals at about every 3 months (+/- 1 month) in these patients until one of the following occurs: local disease progression, transition to hospice, loss of follow up, withdrawal from study or consent, whichever comes first.

Exploratory Objectives:

  1. To evaluate the safety of application of tumor treating fields at frequencies between 150kHZ and 200 KHZ using the TTF-200M and TTF-200A systems (respectively), alone or in combination with available systemic therapy as adjuvant treatment after surgery for spinal cord decompression in patients with refractory spinal metastasis
  2. To assess local spine progression-free survivals at about every 3 months (+/- 1 month) until their local disease progresses, they go to hospice, or are off study, whichever is earlier, in patients in 2.3(a).
  3. To evaluate the safety of application of tumor treating fields at frequencies between 150kHZ and 200 KHZ using the TTF-200M and TTF-200A systems (respectively), alone or in combination with available systemic therapy as adjuvant treatment for patients with radiation refractory spinal metastasis who are unable to undergo surgery due to high risk of complications.
  4. To assess local spine progression-free survivals at about every 3 months (+/- 1 month) until their local disease progresses, they go to hospice, or are off study, whichever is earlier, in patients in 2.3(c).
  5. To evaluate change in plasma ctDNA levels before initiation (baseline) to Cycle 1 and 3.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • The University of Texas M. D. Anderson Cancer Center
        • コンタクト:
        • 主任研究者:
          • Claudio Tatsui, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patients with one or more spinal metastasis(es) affecting levels between C1 to S4 which have been previously treated with surgery and/or maximal doses radiation therapy to the spinal metastasis. For patients in the surgical group, patients must have completed maximal intralesional debulking of their tumor (within 90 days of enrollment).

  2. No more radiation options available for treatment to the spinal metastasis(es) that will undergo the TTF treatment

  3. Male or Female subjects aged ≥ 22 years.

  4. Women of child-bearing potential (women who are not postmenopausal for at least one year or are not surgically sterile) must agree prior to study entry to use adequate contraception (e.g., hormonal, barrier device, or abstinence) for the duration of study participation.

  5. Patients must have a Karnofsky Performance Scale (KPS) (Appendix D) score of at least 70%.

  6. Patients must have the ability to independently disconnect the arrays or turn off the system if they feel uncomfortably hot while using the device.

  7. Patients (and/or legally authorized representative) should be able to fully understand the requirements of the trial, including the need to use the device for at least 18 hours per day, be willing to comply with all trial visits and assessments and be willing and able to sign an Institutional Review Board (IRB) approved written informed consent document (or provide assent where applicable).

  8. Patients with the following tumor histologies (numbers in parenthesis represent the frequencies/device patients with these histologies will be treated with):

    1. Non-small cell lung cancer (150KHZ, TTF-200M)
    2. Chordoma (150KHZ, TTF-200M)
    3. Breast adenocarcinoma (150HKZ, TTF-200M)
    4. Liver/gastrointestinal malignancy (150 KHZ, TTF-200M)
    5. Endocrine origin carcinoma (150KHZ, TTF-200M)
    6. Renal cell carcinoma (200KHZ, TTF-200A)
    7. Prostate adenocarcinoma (200KHZ, TTF-200A)
    8. Sarcoma (200KHZ, TTF-200A)
  9. For the non-surgical group only, expected survival of more than 8 months as confirmed by the primary oncologist.

  10. For the non-surgical group only, in case of multiple noncontiguous vertebral levels requiring treatment, all sites must be included under the largest length of the antero-posterior set of transducer arrays (25cm).

  11. Patients who have previously undergone surgery and already have spinal hardware implanted in the intended area of treatment may be enrolled in the surgical group, regardless of the timing of their original surgery.

Exclusion Criteria:

Patients who meet any of the following exclusion criteria will not be eligible for the study:

  1. Psychiatric illness/social situations (homeless or living in a foreign country) that would limit compliance with study requirements.
  2. Physical or cognitive limitation that prevents the ability to independently disconnect the arrays or turn off the system if they feel uncomfortably hot while using the device. This includes patients that need a legally authorized representative for consent.
  3. Patients in the surgery group who have not fully recovered from the spinal surgery, where wound healing is compromised, requiring healing by second intention (i.e., the wound is left open and heals spontaneously).
  4. History of allergic reactions or sensitivity to conductive hydrogels used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.
  5. Implanted pacemaker, defibrillator, nerve stimulator or other active electronic medical devices in the area of surgery or application of the skin transducers.
  6. Women who are pregnant or lactating.
  7. Prior surgery to the spinal level(s) to be treated with TTF is not an exclusion criterion.
  8. Enrollment on another clinical trial with investigational drugs/devices is not an exclusion criterion and is kept at the discretion of the treating surgeon.
  9. Patients with leptomeningeal disease.
  10. Patients with severe pre-existing dermatological conditions (i.e., active herpes zoster, bullous pemphigoid reactions, Stevens-Johnson syndrome) that might interfere with interpretation of the device's skin toxicity.
  11. Patients receiving targeted therapy (i.e., EGFR inhibitors) who present with severe dermatological reactions at the site(s) to receive treatment with NovoTTF-200A or NovoTTF-200M. Prior treatment and complete resolution of a prior severe dermatological reaction are not exclusion criteria.
  12. Multiple noncontiguous progressive spine tumors separated by more than 25 cm.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:150 kHz(novottf-200m)または200kHz(novottf-200a)での治療

Participants will receive treatment with NovoTTF-200M or NovoTTF-200A and treatment will continue as long as the doctor thinks it is in the participant's best interest.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety and Adverse Events (AEs)
時間枠:Through study completion; an average of 1 year

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Claudio Tatsui, MD、M.D. Anderson Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年8月18日

一次修了 (推定)

2027年2月17日

研究の完了 (推定)

2029年2月17日

試験登録日

最初に提出

2025年3月26日

QC基準を満たした最初の提出物

2025年3月26日

最初の投稿 (実際)

2025年4月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2024-1879
  • NCI-2025-02319 (その他の識別子:NCI-CTRP Clinical Trials Registray)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する